Reintegrating droperidol into emergency medicine practice
- 25 August 2020
- journal article
- research article
- Published by Oxford University Press (OUP) in American Journal of Health-System Pharmacy
- Vol. 77 (22), 1838-1845
- https://doi.org/10.1093/ajhp/zxaa271
Abstract
After a long period of low utilization, droperidol has become easier to obtain in the US market. This comprehensive review discusses the safety, indications, clinical efficacy, and dosing of droperidol for use in the emergency department (ED) setting. In 2001 the US Food and Drug Administration (FDA) mandated a boxed warning in the labeling of droperidol after reports of QT interval prolongation associated with droperidol use. Since that time, it has been difficult to access droperidol in the United States; as a result, many practicing clinicians lack experience in its clinical use. Multiple studies have been conducted to assess the clinical efficacy and safety of droperidol use in ED patients. Results consistently show the safety of droperidol and its clinical efficacy when used as an analgesic, antiemetic, and sedative. Now that droperidol is more widely available for use in the US market, pharmacists and prescribers need to reliably translate safety and efficacy data compiled since 2001 to help ensure appropriate and effective use of the medication. Droperidol is an effective and safe option for the treatment of acute agitation, migraine, nausea, and pain for patients in the ED setting. Healthcare professionals can adopt droperidol for use in clinical practice, and they should become familiar with how to dose and monitor droperidol for safe and effective use.Keywords
This publication has 41 references indexed in Scilit:
- Psychiatric Evaluation of the Agitated Patient: Consensus Statement of the American Association for Emergency Psychiatry Project BETA Psychiatric Evaluation WorkgroupWestern Journal of Emergency Medicine, 2012
- Does Low-dose Droperidol Administration Increase the Risk of Drug-induced QT Prolongation and Torsade de Pointes in the General Surgical Population?Anesthesiology, 2007
- Evidence-based review of the black-box warning for droperidolAmerican Journal of Health-System Pharmacy, 2007
- Droperidol, when used for sedation during ERCP, may prolong the QT intervalGastrointestinal Endoscopy, 2006
- Randomized Clinical Trial Comparing Intravenous Midazolam and Droperidol for Sedation of the Acutely Agitated Patient in the Emergency DepartmentAnnals of Emergency Medicine, 2006
- Effect of Low-dose Droperidol on the QT Interval during and after General AnesthesiaAnesthesiology, 2005
- Droperidol Causes a Dose-dependent Prolongation of the QT IntervalAnesthesia & Analgesia, 1994
- Epidural Droperidol Reduces the Side Effects and Duration of Analgesia of Epidural SufentanilAnesthesia & Analgesia, 1994
- Droperidol versus haloperidol for chemical restraint of agitated and combative patientsAnnals of Emergency Medicine, 1992
- Epidural Droperidol and Morphine for Postoperative PainAnesthesia & Analgesia, 1990